Page last updated: 2024-09-02

ecteinascidin 743 and Adenocarcinoma

ecteinascidin 743 has been researched along with Adenocarcinoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Avendaño, C; Cuesta, Ede L; González, JF; Manguan-García, C; Ortín, I; Perona, R1
Allavena, P; Belli, C; Cangi, MG; Cappio, S; Ceraulo, D; D'Incalci, M; Doglioni, C; Dugnani, E; Garassini, G; Maggiora, P; Piemonti, L; Porcu, L; Reni, M; Zucchetti, M1

Trials

1 trial(s) available for ecteinascidin 743 and Adenocarcinoma

ArticleYear
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2016

Other Studies

1 other study(ies) available for ecteinascidin 743 and Adenocarcinoma

ArticleYear
Pyrazino[1,2-b]isoquinolines: synthesis and study of their cytostatic and cytotoxic properties.
    Bioorganic & medicinal chemistry, 2008, Oct-01, Volume: 16, Issue:19

    Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Cytostatic Agents; DNA Damage; G1 Phase; G2 Phase; HT29 Cells; Humans; Inhibitory Concentration 50; Isoquinolines; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; S Phase; Structure-Activity Relationship

2008